Russell Investments Group Ltd. cut its stake in Stryker Corporation (NYSE:SYK – Free Report) by 4.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 402,425 shares of the medical technology company’s stock after selling 18,537 shares during the period. Russell Investments Group Ltd.’s holdings in Stryker were worth $110,967,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Gables Capital Management Inc. purchased a new position in Stryker during the 2nd quarter worth approximately $25,000. Kilter Group LLC acquired a new position in Stryker in the second quarter valued at $25,000. Highland Investment Advisors LLC acquired a new position in Stryker in the second quarter valued at $25,000. Cornerstone Financial Management LLC raised its holdings in shares of Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after buying an additional 31 shares during the last quarter. Finally, Compass Financial Management LLC purchased a new position in shares of Stryker during the second quarter worth about $27,000. 77.09% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages have weighed in on SYK. Rothschild & Co Redburn lowered their target price on Stryker from $360.00 to $336.00 in a research note on Monday, November 2nd. Barclays reduced their price objective on shares of Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research report on Friday, October 30th. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research note on Thursday, October 29th. Piper Sandler raised their target price on Stryker from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Monday, November 9th. Finally, Citizens Jmp lowered their price target on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a research note on Friday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $342.19.
Check Out Our Latest Research Report on Stryker
Insider Transactions at Stryker
In related news, Director Ronda E. Stryker sold 550,000 shares of the stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $325.32, for a total value of $178,926,000.00. Following the sale, the director directly owned 1,701,375 shares of the company’s stock, valued at approximately $553,491,315. This represents a 24.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 901,267 shares of company stock valued at $297,123,701 in the last 90 days. 4.60% of the stock is currently owned by insiders.
Stryker Stock Performance
Shares of SYK stock opened at $309.05 on Monday. The stock has a fifty day moving average price of $292.30 and a 200 day moving average price of $322.60. The stock has a market cap of $117.65 billion, a PE ratio of 32.91, a P/E/G ratio of 2.13 and a beta of 0.78. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18.
Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period last year, the company posted $3.19 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.85 earnings per share for the current fiscal year.
About Stryker
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
See Also
- Five stocks we like better than Stryker
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
